Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TICAP-DCM: Cardiac Progenitor Cell Therapy in Children With Dilated Cardiomyopathy
NCT03129568Phase 1Completed
- Sponsor
- Okayama University
- Start
- Apr 2017
- Primary completion
- Sep 2018
- Modality
- Mesenchymal Stem Cells, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deramiocel in dilated cardiomyopathy (DCM), sponsored by Okayama University. Primary endpoint: Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs at 6 months. Started Apr 2017; status: completed.
02
Drugs
deramiocel
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT03129568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03129568.